Table 1.
Utilisation of different mAbs in B&H broken down by originator and biosimilar 2017–2019.
| ATC Code | INN | Brand name | Pharmaceutical form | Dosage and quantity | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|
| Utilisation | Utilisation | Utilisation | |||||
| L01XC02 | Rituximab | MABTHERA | Concentrate for solution for infusion | 100 mg/10 mL | 1612 | 1261 | 723 |
| Solution for injection | 120 mg/1 mL | 13 | 443 | NM | |||
| Concentrate for solution for infusion | 500 mg/50 mL | 1778 | 1527 | 961 | |||
| Solution for subcutaneous injection | 1400 mg/11.7 mL | NM | NM | 1216 | |||
| Solution for subcutaneous injection | 1600 mg/13.4 mL | NM | NM | 3 | |||
| BLITZIMA | Concentrate for solution for injection/infusion | 10 mg/1 mL | NA | NM | NM | ||
| ACELLBIA | Concentrate for solution for infusion | 10 mg/1 mL | NA | NA | NA | ||
| Concentrate for solution for infusion | 10 mg/1 mL | NA | NA | NA | |||
| RIXATHON | Concentrate for solution for infusion | 10 mg/1 mL (10 mL) | NA | NM | NM | ||
| Concentrate for solution for infusion | 10 mg/1 mL (2 × 10 mL) |
NA | NM | NM | |||
| Concentrate for solution for infusion | 10 mg/1 mL (50 mL) | NA | NM | NM | |||
| Concentrate for solution for infusion | 10 mg/1 mL (2 × 50 mL) |
NA | NM | NM | |||
| L01XC03 | Trastuzumab | HERCEPTIN | Powder for concentrate for solution for infusion | 150 mg | 5969 | 5929 | 4568 |
| HERCEPTIN | Solution for injection | 600 mg/5 mL | 2810 | 3014 | 3885 | ||
| HERTICAD | Powder for concentrate for solution for infusion | 150 mg | NA | NA | NA | ||
| KANJINTI | Powder for concentrate for solution for infusion | 150 mg | NA | NA | NA | ||
| KANJINTI | Powder for concentrate for solution for infusion | 420 mg | NA | NA | NA | ||
| OGIVRI | Powder for concentrate for solution for infusion | 150 mg | NA | NA | NM | ||
| HERZUMA | Powder for concentrate for solution for infusion | 420 mg | NA | NA | NA | ||
| HERZUMA | Powder for concentrate for solution for infusion | 150 mg | NA | NA | NA | ||
| L04AB02 | Infliximab | REMICADE | Powder for concentrate for solution for infusion | 100 mg | 975 | 1180 | 1605 |
| REMSIMA | Powder for concentrate for solution for infusion | 100 mg | 420 | 450 | 520 | ||
| INFLECTRA | Powder for concentrate for solution for infusion | 100 mg | 671 | 81 | 74 | ||
| L04AB04 | Adalimumab | HUMIRA | Solution for injection | 40 mg/0.8 mL | 1152 | 320 | NM |
| HUMIRA | Solution for injection in pre-filled syringe | 40 mg/0.4 mL | 500 | 1899 | 2605 | ||
| AMGEVITA | Solution for injection in pre-filled syringe | 40 mg/0.8 mL | NA | NA | 20 | ||
| AMGEVITA | Solution for injection in pre-filled syringe | 20 mg/0.4 mL | NA | NA | NM | ||
| AMGEVITA | Solution for injection in pre-filled pen | 40 mg/0.8 mL 2 pre-filed pens |
NA | NA | NM | ||
| HULIO | Solution for injection | 40 mg/0.8 mL 1 pre-filled pen |
NA | NA | NA | ||
| HULIO | Solution for injection in pre-filled syringe | 40 mg/0.8 mL 2 pre-filled syringes |
NA | NA | NA | ||
| HULIO | Solution for injection in pre-filled syringe | 40 mg/0.8 mL 1 pre-filled syringe with 2 alcohol pads |
NA | NA | NA | ||
| HULIO | Solution for injection in pre-filled syringe | 40 mg/0.8 mL 2 pre-filled syringes with 2 alcohol pads |
NA | NA | NA |
Shaded: biosimilar; NM: not marketed; NA: not approved.